Shanghai Fengxian Investment Co., Ltd. completed the acquisition of 10% stake in Shanghai Fudan Forward Pharmaceutical Co., Ltd. from Shanghai Fudan Forward S&T Co., Ltd
September 22, 2020
Share
Shanghai Fengxian Investment (Group) Co., Ltd. agreed to acquire 10% stake in Shanghai Fudan Forward Pharmaceutical Co., Ltd. from Shanghai Fudan Forward S&T Co., Ltd (SHSE:600624) for nil consideration on December 31, 2019. In related transaction, Shanghai Fengxian Investment (Group) Co., Ltd. acquires 18.74% stake in Shanghai Fudan Forward S&T Co., Ltd (SHSE:600624). The transaction has been approved by the Ministry of Education of the People's Republic of China and is still subject to official approval from Shanghai Fengxian District State-owned Assets Supervision and Administration Commission and Shanghai Fengxian District People's Government. Post the acquisition, Shanghai Fudan Forward S&T Co., Ltd (SHSE:600624) will own 90% stake in Shanghai Fudan Forward Pharmaceutical Co., Ltd.
Shanghai Fengxian Investment (Group) Co., Ltd. completed the acquisition of 10% stake in Shanghai Fudan Forward Pharmaceutical Co., Ltd. from Shanghai Fudan Forward S&T Co., Ltd (SHSE:600624) on September 23, 2020.
SHANGHAI FUDAN FORWARD S&T CO., LTD is a China-based company, principally engaged in the manufacture and distribution of pharmaceuticals. The Company's pharmaceuticals include digestive system drugs, nervous system drugs, antineoplastic drugs, circulatory drugs, immune function medications and others. The Company is also engaged in the provision of financial insurance software products. It distributes its products within domestic markets and to overseas markets.
SHANGHAI FUDAN FORWARD S&T CO., LTD 
